proglumide has been researched along with Fibrosis in 5 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 5.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| "Two murine models were used to determine whether CCK receptor blockade with proglumide could prevent and reverse histologic and biochemical features of chronic pancreatitis: the 6-week repetitive chronic cerulein injection model and the modified 75% choline-deficient ethionine (CDE) diet." | 3.96 | Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis. ( Cao, H; Ciofoaia, V; Kallakury, B; Nadella, S; Smith, JP; Tucker, RD, 2020) |
| "Proglumide was well tolerated at all doses without any serious adverse events." | 3.11 | Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis. ( Bansal, S; Cao, H; Cheema, A; Gay, MD; Kwagyan, J; Lewis, JH; Nadella, S; Rabiee, A; Shivapurkar, N; Smith, CI; Smith, JP, 2022) |
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 1.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabiee, A | 1 |
| Gay, MD | 2 |
| Shivapurkar, N | 3 |
| Cao, H | 3 |
| Nadella, S | 3 |
| Smith, CI | 1 |
| Lewis, JH | 1 |
| Bansal, S | 1 |
| Cheema, A | 1 |
| Kwagyan, J | 1 |
| Smith, JP | 5 |
| He, AR | 1 |
| Chen, W | 1 |
| Golnazar, S | 1 |
| Duka, T | 1 |
| Kallakury, B | 2 |
| Vasudevan, S | 1 |
| Ciofoaia, V | 1 |
| Tucker, RD | 2 |
| Burks, J | 1 |
| Al-Sabban, A | 1 |
| Inyang, G | 1 |
| Wang, J | 1 |
| Zamanis, ME | 1 |
| Bukowski, W | 1 |
| Cooper, TK | 1 |
| McGovern, CO | 1 |
| Gilius, EL | 1 |
| Zhong, Q | 1 |
| Liao, J | 1 |
| Molinolo, AA | 1 |
| Gutkind, JS | 1 |
| Matters, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH)[NCT04152473] | Phase 1 | 18 participants (Actual) | Interventional | 2019-12-13 | Completed | ||
| A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months[NCT05551858] | Phase 1/Phase 2 | 32 participants (Anticipated) | Interventional | 2022-11-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for proglumide and Fibrosis
| Article | Year |
|---|---|
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Topics: Cholecystokinin; Fibrosis; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Proglu | 2022 |
4 other studies available for proglumide and Fibrosis
| Article | Year |
|---|---|
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholecystokinin; Fibrosis; Immune Checkpoint Inhibitors; Liver N | 2023 |
Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.
Topics: Animals; Ceruletide; Chronic Disease; Disease Models, Animal; Fibrosis; Inflammation; Lipase; Mice; | 2020 |
Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dietary Fats; Female; Fibrosis; Male; Mice; Mice, | 2018 |
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
Topics: Animals; Carcinoma in Situ; Cholecystokinin; Disease Progression; Drug Screening Assays, Antitumor; | 2014 |